Tharimmune (NASDAQ:THAR) Trading Down 5.9% – Should You Sell?

Tharimmune, Inc. (NASDAQ:THAR) shares dropped 5.9% during mid-day trading on Thursday . The company traded as low as $2.20 and last traded at $2.22. Approximately 654,343 shares were traded during trading, an increase of 153% from the average daily volume of 258,752 shares. The stock had previously closed at $2.36.

Wall Street Analyst Weigh In

Several analysts have issued reports on THAR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tharimmune in a report on Monday. Wall Street Zen upgraded Tharimmune from a “sell” rating to a “hold” rating in a research report on Sunday, October 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Tharimmune Stock Performance

The company has a market capitalization of $80.90 million, a PE ratio of -0.56 and a beta of 1.43. The stock’s fifty day simple moving average is $2.84 and its 200-day simple moving average is $2.55.

Tharimmune (NASDAQ:THAR) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.09.

Institutional Investors Weigh In On Tharimmune

Several hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. purchased a new stake in shares of Tharimmune in the second quarter valued at $88,000. XTX Topco Ltd purchased a new position in Tharimmune during the second quarter worth about $25,000. Finally, Drucker Wealth 3.0 LLC acquired a new stake in Tharimmune in the 3rd quarter worth about $29,000. Institutional investors and hedge funds own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).